Preparation and characterization of yeast cell wall beta-glucan encapsulated humic acid nanoparticles as an enhanced aflatoxin B1 binder

Hamza, Zeinab K; El‐Hashash, M. A.; Aly, Soher E.; Hathout, Amal S.; Soto, Ernesto; Sabry, Bassem A.; Ostroff, Gary R.

doi:10.1016/j.carbpol.2018.08.047

Cited by 38 publications

(24 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The synergistic activity used lower doses of combined form than each alone. Hamza et al [ 112 ] used hybrid β-glucan mannan lipid particles (GMLPs)-humic acid iron nanoparticles (HA-FeNPs) as an AFB1 binder provides a high binding capacity and a safe enhanced mycotoxin binding material.…”

Section: Applications Of Nanoantifungals In Veterinary Medicinementioning

confidence: 99%

“…Nanoantifungals and their hybrids have the potential to penetrate cancer cells and accumulate in the cytoplasm of cancer cells leading to damage, followed by an inhibitory action leading to death [ 111 ]. Similar properties of nanoparticles can help in early and reliable detection of various types of cancer tissues [ 112 ]. Hybrid nanocarrier and natural body sugars-derived NPs can help in carrying and release of drugs as in cases of lung cancer [ 88 ].…”

Section: Applications Of Nanoantifungals In Veterinary Medicinementioning

confidence: 99%

See 1 more Smart Citation

Antifungal Nano-Therapy in Veterinary Medicine: Current Status and Future Prospects

Alghuthaymi

Hassan

Kalia

et al. 2021

JoF

View full text Add to dashboard Cite

The global recognition for the potential of nanoproducts and processes in human biomedicine has given impetus for the development of novel strategies for rapid, reliable, and proficient diagnosis, prevention, and control of animal diseases. Nanomaterials exhibit significant antifungal and antimycotoxin activities against mycosis and mycotoxicosis disorders in animals, as evidenced through reports published over the recent decade and more. These nanoantifungals can be potentially utilized for the development of a variety of products of pharmaceutical and biomedical significance including the nano-scale vaccines, adjuvants, anticancer and gene therapy systems, farm disinfectants, animal husbandry, and nutritional products. This review will provide details on the therapeutic and preventative aspects of nanoantifungals against diverse fungal and mycotoxin-related diseases in animals. The predominant mechanisms of action of these nanoantifungals and their potential as antifungal and cytotoxicity-causing agents will also be illustrated. Also, the other theragnostic applications of nanoantifungals in veterinary medicine will be identified.

show abstract

Section: Applications Of Nanoantifungals In Veterinary Medicinementioning

confidence: 99%

Section: Applications Of Nanoantifungals In Veterinary Medicinementioning

confidence: 99%

Antifungal Nano-Therapy in Veterinary Medicine: Current Status and Future Prospects

Alghuthaymi

Hassan

Kalia

et al. 2021

JoF

View full text Add to dashboard Cite

show abstract

“…Conversely, the AFT-albumin adduct with a longer half-life of www.bosaljournals/chemint/ editorci@bosaljournals.com 30-60 days, relative stability and minimum variability can be estimated in peripheral blood to measure the long-term AFT exposure (Williams et al, 2004). Results revealed that various factors are responsible for AFTs production and all living organisms are vulnerable for its toxic effects (Asare Bediako et al, 2019;Blankson et al, 2019;Cheng et al, 2019;Dí az Nieto et al, 2019;Frisvad et al, 2019;Gummadidala et al, 2019;Hamza et al, 2019;Magzoub et al, 2019;Mwakinyali et al, 2019;Shahbazi and Shavisi, 2019;Singh and Cotty, 2019;Tsounidi et al, 2019;Wang et al, 2019a;Wang et al, 2019b;Wu et al, 2019;Xie et al, 2019a;Xie et al, 2019b;Yu et al, 2019;Zeng et al, 2019;Zhao et al, 2019;Zhou et al, 2019). So far, there is need to develop the detoxification methods to save food and feed items without harming the nutritional and sensory characteristics.…”

Section: Detection and Exposure Assessment Of Aftsmentioning

confidence: 99%

Aflatoxins biosynthesis, toxicity and intervention strategies: A review

Int¹

2019

Preprint

View full text Add to dashboard Cite

Aflatoxins (AFTs) are toxic products of fungal metabolism, associated with serious health consequences and substantial economic losses to agriculture, livestock and poultry sectors, particularly in the developing countries. This review outlines the current information on AFTs in terms of historical background, classification, relative occurrence and co-existence with other mycotoxins in various food commodities. The phenomenon of aflatoxin (AFT) biosynthesis has been elucidated with reference to molecular basis, genetic regulation and factors affecting the AFT production. Moreover, the in vivo disposition kinetics, toxicological action and toxico-pathological consequences of AFTs have also been highlighted. Currently employed strategies for the detection and detoxification of AFTs, biomarkers of exposure assessment, potential economic impact and regulatory considerations regarding the AFTs have been emphasized.

show abstract

“…Saccharomyces cerevisiae that provide an efficient system for encapsulation, transport, delivery, and release of a wide range of molecules [25] such as water-soluble macromolecules and insoluble preformed nanoparticles (NPs) of less than 30 nm in diameter as cores inside GMLP (GMLP-NP) or onto the surface of GMLPs [26,27].…”

Section: Glucan Mannan Lipid Particles Are 3-4 μM Hollow and Porous Mmentioning

confidence: 99%

Chemical remediation of Aflatoxin B1 using encapsulated polyvinylpyrrolidone as an environmental-friendly control.

et al. 2019

Self Cite

View full text Add to dashboard Cite

A FLATOXINS (AFs) are difuranocoumarin derivatives produced as secondary metabolites by fungi belonging to several Aspergillus species. Aflatoxin B 1 (AFB 1) is one of the most potent naturally occurring hepatic carcinogens to both human and animals and is classified as a group (1) human carcinogen. Therefore, the aim of this study is to assess the effect of encapsulating polyvinylpyrrolidone (PVP 10, 360 and 1300 kDa)-Tannic acid complexed nanoparticles (PVP-TA NPs) inside yeast cell walls (YCW) to remediate AFB 1 in the gastrointestinal models. Glucan Mannan Lipid Particles (GMLPs) from Saccharomycesces cerevisie cell walls showed the highest AFB 1 adsorption in simulated gastric fluid (SGF) after 10 min, and in simulated intestinal fluid (SIF) after1 h. Glucan Mannan Lipid Particles are hollow 3-4-micron porous microspheres that provide an efficient system for the synthesis and encapsulation of AFB 1-absorbing nanoparticles (NPs). Although tannic acid (28%) was released from GMLP particles after three water washes, only 10, 5.6 and 7.6% of the total loaded TA was released when complexed with optimal ratios of PVP 10, 360 and 1300 kDa; respectively. Fluorescence microscopic images supported the conclusion that PVP TA complexed NP cores were successfully synthesized inside the GMLPs. Encapsulation of PVP TA NPs inside GMLPs significantly increased the stability of the GMLP encapsulated PVP TA NPs formulation. Data also showed that AFB 1 adsorption by the multi-functional GMLP PVP-TA NPs was enhanced synergistically in SGF and in SIF binding compared to individual GMLP.

show abstract

Preparation and characterization of yeast cell wall beta-glucan encapsulated humic acid nanoparticles as an enhanced aflatoxin B1 binder

Cited by 38 publications

References 41 publications

Antifungal Nano-Therapy in Veterinary Medicine: Current Status and Future Prospects

Antifungal Nano-Therapy in Veterinary Medicine: Current Status and Future Prospects

Aflatoxins biosynthesis, toxicity and intervention strategies: A review

Chemical remediation of Aflatoxin B1 using encapsulated polyvinylpyrrolidone as an environmental-friendly control.

Contact Info

Product

Resources

About